In summary, in iodine-refractory DTC patients undergoing treatment with lenvanitib, serum Tg fluctuations are a frequent phenomenon that do not necessarily reflect morphologic tumor alterations in these patients, especially shortly after lenvatinib dose reductions. This evidence concerns the gene TG and neoplasm.